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1. Introduction 
Since the first implant in 1980, the implantable cardioverter defibrillator (ICD) has become 
the first line therapy for sudden cardiac death and it’s technology has developed from a 
non-programmable device into a sophisticated multi-programmable, multi-functional 
device with extensive diagnostic and therapeutic options [1,2]. Programmable options of the 
new generation ICDs include arrhythmia detection, tachyarrhythmia therapy, pacing 
function, and stored intracardiac data. 
An ICD consists of pulse generator, endocardial electrode, and defibrillation coils. ICD 
senses the rhythm and detects ventricular tachycardia (VT) and/or ventricular fibrillation 
(VF) and may deliver the following antitachycardia therapies [2,3]:  
1. Anti-tachycardia pacing (ATP), 
2. Low energy cardioversion, 
3. High energy defibrillation. 
All ICDs are programmed several heart rate zones to detect tachyarrhythmia. The VF zone 
is programmed to a rapid heart rate, often with a heart rate of ≥180 bpm. Monomorphic and 
stable VT may allow to program other therapy zones such as ATP. ATP may allow 
termination of a tachyarrhythmia via pacing impulses that are faster than the underlying VT 
rate and prevent defibrillator shocks (Figure 1-2) [2,4]. 
Randomized clinical secondary prevention trials have demonstrated the effectiveness of ICD 
therapy for arrhythmic death and total mortality in survivors of cardiac arrest [5]. Syncope 
of undetermined origin with inducible ventricular tachyarrhythmias is also indication for 
ICD implantation. Low incidence of sudden cardiac death and high incidence of appropriate 
ICD therapy has been shown in patients with syncope of undetermined origin and inducible 
ventricular tachyarrhythmias at follow-up [6]. Prophylactic therapy in patients at risk for 
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sudden cardiac death (primary prevention) was first based on the results of MADIT, 
MUSTT, and MADIT ƖƖ, then later expanded upon results from SCD-HeFT [7-9]. Multiple 
randomized ICD trials reported that ICD benefit increases dramatically with time [10]. 
Indications for ICDs have expanded considerably since approval of the first ICD in 1985 
[11]. Table 1 and 2 summarizes the Class I and Class II indications for ICD implantation in 
adults [11,12]. In this section we discuss ICD-releated problems including implantation of 
device detection and therapy of VT/VF. 
 
 
Figure 1. Stored ventricular electrogram showing a successful anti-tachycardia pacing (ATP) therapy, 
converting a rapid ventricular tachycardia to sinus rhythm. 
 
 
Figure 2. Stored atrial and ventricular electrogram showing a successful anti-tachycardia pacing (ATP) 
therapy, converting a rapid ventricular tachycardia to sinus rhythm. 
 
Class I
1. Survivors of cardiac arrest due to VT or VF not due to a reversible cause.
2. Spontaneous sustained VT in association with structural heart disease.
3. Syncope of undetermined origin with clinically relevant, hemodynamically significant 
sustained VT or VF induced at EPS.
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Class I
4. Patients with LVEF less than or equal to 35% due to prior MI who are at least 40 days 
post-MI and are in NYHA functional Class II or III.
5. Patients with nonischemic DCM who have an LVEF less than or equal to 35% and who 
are in NYHA functional Class II or III.
6. Patients with LV dysfunction due to prior MI who are at least 40 days post-MI, have an 
LVEF less than or equal to 30%, and are in NYHA functional Class I. 
7. Nonsustained VT due to prior MI, LVEF less than or equal to 40%, and inducible VF or 
sustained VT at EPS. 
Abbreviations: DCM, Dilated Cardiomyopathy; EPS, Electrophysiologic Study; LVEF, Left Ventricular Ejection 
Fraction; MI, Myocardial Infarction; NYHA, New York Heart Association; VF, Ventricular Fibrillation; VT, Ventricular 
Tachycardia. 
Reproduced from Epstein AE, Dimarco JP, Ellenbogen KA et al: ACC/AHA/HRS 2008 Guidelines for device-based 
therapy of cardiac rhythm abnormalities. a report of the American College of Cardiology/American Heart Association 
task force on practice guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for 
Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) JACC 2008;51: e1-e62. 
Table 1. Indications of ICD Implantation in Adults 
 
Class IIa
1. Unexplained syncope, significant LV dysfunction, and nonischemic DCM. 
2. Sustained VT and normal or near-normal ventricular function. 
3. ARVD/C who have 1 or more risk factors* for SCD. 
4. HCM who have 1 or more major risk factors† for SCD. 
5. Brugada syndrome who have had syncope. 
6. Brugada syndrome who have documented VT that has not resulted in cardiac arrest. 
7. Catecholaminergic polymorphic VT who have syncope and/or documented sustained VT 
while receiving beta blockers. 
8. Long-QT syndrome who are experiencing syncope and/or VT while receiving beta 
blockers. 
9. Non hospitalized patients awaiting transplantation. 
10. Cardiac sarcoidosis, giant cell myocarditis, or chagas disease. 
Class IIb 
1. Nonischemic heart disease who have an LVEF of less than or equal to 35% and who are 
in NYHA functional Class I. 
2. Familial cardiomyopathy associated with sudden death. 
3. Long-QT syndrome and risk factors for SCD. 
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Class IIb 
4. LV noncompaction. 
5. Syncope and advanced structural heart disease in whom thorough invasive and 
noninvasive investigations have failed to define a cause. 
Abbreviations: ARVD/C, Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy; CABG, Coronary Artery 
Bypass Grafting; DCM, Dilated Cardiomyopathy; EPS, Electrophysiologic Study; HCM, Hypertrophic 
Cardiomyopathy; LVEF, Left Ventricular Ejection Fraction; NYHA, New York Heart Association; SCD, Sudden 
Cardiac Death; VF, Ventricular Fibrillation; VT, Ventricular Tachycardia. 
* The risk factors include induction of VT during electrophysiological testing, detection of nonsustained VT on 
noninvasive monitoring, male gender, severe RV dilation, and extensive RV involvement. 
† The major risk factors include prior cardiac arrest, spontaneous sustained VT, spontaneous nonsustained VT, family history 
of SCD, syncope, LV thickness greater than or equal to 30 mm, and an abnormal blood pressure response to exercise. 
Reproduced from Epstein AE, Dimarco JP, Ellenbogen KA et al: ACC/AHA/HRS 2008 Guidelines for device-based 
therapy of cardiac rhythm abnormalities. a report of the American College of Cardiology/American Heart Association 
task force on practice guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for 
Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) JACC 2008;51: e1-e62. 
Table 2. Indications of ICD Implantation in Adults 
1.1. Implantable cardioverter defibrillator related problems 
In the early years, ICD’s generator was implanted in the abdomen and epicardial leads and 
patches were placed via thoracotomy associated with significant morbidity and mortality [2]. 
With the new generation of endocardial leads and significant reduction in size of the devices, 
the procedure can be performed under local anaesthesia. Moreover, ICD generator is implanted 
in the pectoral region and endocardial lead is positioned at the right ventricular apex [2,3].  
The ICD related problems can be classified as mechanical complications and pacing system 
malfunction including detection and therapy of VT/VF (Table 3). Mechanical complications 
are related to implantation procedure such as pneumothorax, hemothorax, subclavian artery 
puncture, thrombosis, pocket hematoma, infection, lead dislodgement, and myocardial 
perforation [3,13,14].  
Venous access can be administered via the cephalic, subclavian, or axillary vein for ICD 
implantation and pneumothorax is mostly associated with the blind puncture approach of 
the subclavian vein. Review of randomized clinical trials showed that the incidence of 
pneumothorax was low and observed approximately 0,9% [13]. 
 
Mechanical Complications Pacing system malfunction 
Pneumothorax Shocks delivered by the device 
 Inappropriate ICD Shock 
 Electrical Storm Hemothorax
Subclavian artery puncture
Thrombosis
Pocket hematoma Ineffective Therapy 
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Mechanical Complications Pacing system malfunction 
Infection Drug Effects on ICD 
Lead dislodgement, and myocardial 
perforation
ICD-Pacemaker Interactions 
Table 3. Implantable cardioverter defibrillator related problems 
Pocket hematoma is not directly life threatening, but it may increase the risk of infection. 
Pocket hematoma was observed approximately 2,2% in clinical trials [13,15]. Infection is a 
rare complication of pacemaker and ICD implantation, with the incidence ranging from 
0,8% to 5,7%. Clinical manifestations include skin infection, pocket infection, and 
endocarditis. Staphylococcus aureus and S. epidermidis are the most common organisms 
[3]. Endocarditis has a fearful mortality rate as high as 27% [16]. Randomized clinical trials 
demonstrated that infection rates decreased with routine use of antibiotic prophylaxis at the 
time of implantation or generator change and hence routine prophylaxis with 
antistaphylococcal antibiotics is recommended [3,17]. 
Venous thrombosis in the subclavian vein and superior vena cava was observed in 14% of 
pacemaker and ICD implantations in a prospective trial. Clinical manifestations vary from 
subclinical to superior vena cava obstruction syndrome [18]. Intracardiac thrombosis 
generally occurs in the right atrium around the lead. The size and location of the thrombus 
determine the clinical manifestation. Intravascular and intracardiac thrombosis may cause 
acute or recurrent pulmonary embolism. Treatment is usually initiated with intravenous 
heparinization and followed by oral anticoagulation [3]. 
Lead dislodgement with myocardial perforation is a rare complication with an incidence of 
<1% and it is defined as perforation of a device lead through the myocardium. Clinical 
manifestations vary from asymptomatic to sudden cardiac death [14]. 
Pacing system malfunction can be grouped into following categories [2,3,19]. 
1. Shocks delivered by the device 
a. Inappropriate ICD Shock 
b. Electrical Storm 
2. Ineffective Therapy 
3. Drug Effects on ICD 
4. ICD-Pacemaker Interactions 
2. Shocks delivered by the device 
Although randomized clinical trials have demonstrated the effectiveness of ICD therapy, 
both appropriate and inappropriate ICD shocks are painful, physically and mentally 
disturbing, and potentially arrhythmogenic. In addition, inappropriate shocks are associated 
with a higher risk of all-cause mortality [20,21]. Even appropriate ICD shocks increase 
mortality, mostly due to progressive heart failure [22]. Most single shocks are appropriately 
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delivered to therapy of VT/VF, but multiple shocks are more often classified as 
inappropriate [2]. When a patient presents with an ICD shock, history, physical 
examination, and device interrogation should be performed. Stepwise approach for patients 
with ICD shock is essential and the first step is to differentiate a real tachycardia from a 
device recorded tachycardia originating from another source (Figure 3) [2,19].  
 
Figure 3. Stepwise Algoritm for Patients with ICD Shock. Adapted from van Erven L, Schalij MJ. 
Arrhythmias: Troubleshooting implantable cardioverter-defibrillator related problems. Heart 
2008;94(5):649-60. Abbreviations: EMI, Electromagnetic interference; ICD, implantable cardioverter 
defibrillator; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular 
tachycardia. 
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2.1. Inappropriate ICD shock 
Inappropriate shock is the most common adverse effect observed among ICD patients and 
the incidence varies from 13% to 22% [21-24]. Inappropriate shock may be caused by 
misdiagnosis of supraventricular tachycardia (SVT) as VT/VF or inappropriate sensing 
originating from internal and external sources (Table 4) [2,21]. These sensed events must 
occur at a rate higher than the programmed cut-off rate [2]. Atrial fibrillation (AF) is the 
most common cause of inappropriate shock, followed by sinus tachycardia, atrial flutter, 
atrial tachycardia and less commonly other types of SVT, like atrioventricular nodal 
reentry tachycardia [19,25,26]. History of AF, younger age, no statin use, interim 
appropriate shocks, a maximal heart rate during exercise close to the detection interval, 
and a low cut-off rate for VT-detection have been found to be independent risk factors for 
inappropriate shock [21,26]. 
Various algorithms, including tachyarrhythmia stability, sudden onset, and morphology of 
rhythm have been developed to discriminate between SVT and ventricular arrhythmias. 
Sinus tachycardia is differentiated from VT based on sudden onset criterion. While sinus 
tachycardia increases gradually, VT has a sudden increase in ventricular rate. But this 
criterion might not differentiate slow VT from the sinus tachycardia due to minimal cycle 
length difference [27,28]. Stability algorithm based on regularity of VT is an effective 
discriminator to differantiate AF from VT; however, AF with faster ventricular rate can be 
regular and VT can show some irregularity. Ventricular arrhythmias have different origin 
and wave form, resulting in a morphology district from supraventricular rhythm. These 
criteria help to discriminate between SVT and ventricular arrhythmias [2]. It is important to 
remember that these discriminators don’t work in the VF zone and hence adjusting 
detection intervals and therapy zones more carefully may reduce recurrent shocks. In 
addition, the use of medications and/or appropriate ablation procedure may prevent 
recurrences of SVT [19,29]. 
 
Tachycardia Related Causes Non-Tachycardia Related Causes 
Supraventricular Tachycardia 
 Atrial Fibrillation (most common) 
 Sinus Tachycardia 
 Atrial Flutter 
 Atrial Tachycardia 
 Other Types of Arrhythmia (like 
AVNRT) 
Oversensing of Intracardiac Signals 
 Oversensingof P or T Wave 
 Double Counting of R Wave 
 Sensing of Pacemaker Artifact 
Oversensing of Extracardiac Signals 
 Conductor or Connector Defect 
 Myopotentials 
 Electromagnetic Interference 
Abbreviations: AVNRT, Atrioventricular Nodal Reentry Tachycardia; ICD, implantable cardioverter defibrillator. 
Table 4. Causes of Inappropriate ICD Shocks 
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When the device interrogation doesn’t reveal a real tachycardia, the device recorded signals 
originate from intracardiac or extracardiac sources (Table 4) [2,30]. Oversensing of P or T 
wave and double counting of R wave are easily diagnosed from intracardiac 
electrocardiograms. T-wave oversensing occurs more frequently during exercise. A high T 
wave amplitude, a low R wave amplitude and younger age may contribute to T wave 
oversensing as a cause of inappropriate shocks. T wave oversensing and double counting of 
R wave can be managed by reprogramming the sensitivity level of ICD [2,30]. Device-
related causes of inappropriate shocks include inappropriate sensing due to lead/device 
malfunction or dislodgement. Conductor defect or connector problems are associated with 
postural changes. Impedance may be within normal limits. On the other hand, if lead 
impedance is high, conductor fracture should be suspected, while low lead impedance is 
associated with insulation defect. Insulation defect may lead to oversensing of signals and 
inappropriate shocks. Upper extremity isometric exercises, deep breathing may lead to 
diaphragmatic oversensing and cause inappropriate shocks [2,19]. Electromagnetic 
interference (EMI) is recognised as high frequency, low amplitude signals that refers to 
noise on the ventricular channel from environmental sources. Potential sources of EMI are 
listed in Table 5. It is believed that using household appliances, such as televisions, radios, 
microwaves, toasters, and electric blankets do not effect functions of ICDs. A detailed 
history is useful in the diagnosis of this problem [2,19,31 ]. 
 
Non-Medical Sources Medical Sources
 Electronic Article Surveillance Devices 
 Cellular Phones 
 Metal Detector Gates 
 Arc Welding 
 Transthoracic Cardioversion 
 Magnetic Resonance Imaging 
 Radiation Therapy 
 Electrocautery 
 Lithotripsy 
Table 5. Sources of Electromagnetic Interference 
2.2. Electrical storm 
Electrical storm refers to the occurrence of three or more episodes of VT or VF in a 24-hour 
period and it is associated with episodes of ATP (Figure 4) and/or multiple shocks (Figure 5) 
[3,32]. A patient with electrical storm should be immediately hospitalized and monitorized 
to determine the appropriateness of the shocks. Intravenous amiodarone is the first line 
therapy and the first step is to evaluate reversible causes of VT/VF such as electrolyte 
abnormality and ischemia. All clinicians should keep in mind that proarrhythmic effects of 
antiarrhythmic drugs may also lead to electrical storm. Intravenous β-blockers to suppress 
adrenergic stimulation, intubation and sedation, anti-ischemic therapy, intra-aortic balloon 
pump and ventricular assist devices for hemodynamic support have been used to suppress 
the ventricular arrhythmias. The ICD can be interrogated to ascertain programmed 
parameters to attempt pace termination of VT. Catheter ablation of VT/VF may be used as a 
last treatment way in selected patients [3,32,33]. 
 








Figure 4. Continuous intracardiac electrogram recordings from interrogation of an ICD in a 56-year-old 






Figure 5. Continuous intracardiac electrogram recordings from interrogation of an ICD in a 62-year-old 
man with sustained VT. Electrical storm terminates with three episodes of high-energy defibrillation. 
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3. Ineffective therapy 
Ineffective therapy refers to delayed or absent ICD therapy delivery during VT/VF and it can 
be lethal [2,3]. Undersensing and lack of detection of VT/VF, and device related problems are 
the main causes of ineffective ICD therapy. Lead malfunction or displacement, generator 
malfunction, exposure to EMI, use of antiarrhythmic drug, and pacemaker-ICD interaction 
may cause undersensing of VT/VF. High cut-off rate for detection, battery depletion with 
prolonged charge time, exposure to EMI, and slower VT may obstruct the detection of VT/VF 
[3]. Consequently, device failure have resulted in unnecessary deaths. Although these deaths 
may be infrequent, patients with an ICD should be evaluated to assess the battery status, 
charge time, lead integrity and function, and underlying rhythm every three months and after 
each exposure to EMI [3,34]. Alternatively, if remote monitoring is used, the office follow-up 
may be spaced out according to the recent HRS/EHRA guideline [35]. 
4. Drug effects on ICD 
The primary indications to initiate antiarrhythmic agents in patients with ICD are 
suppression of the burden of the arrhythmias. Antiarrhythmic drug use has been reported 
to range from 49% to 69% in various trials [36]. Adding concomitant therapy with 
antiarrhythmic drugs to ICD patients results in following beneficial effects [3,36,37]:  
1. Reduction in frequency of ICD therapy by decreasing the episodes of VT/VF or making 
them nonsustained, 
2. Reduction of VT rate to allow ATP therapy, 
3. Reduction in the frequency of recurrence of SVT to prevent inappropriate shocks, 
4. Reduction in the defibrillation threshold (DFT), 
5. Improvement in quality of life. 
Although evidence supports above beneficial effects, the potential deleterious effects of 
antiarrhythmic drugs on ICD function include [3,36,37]: 
1. Increased ICD discharge due to proarrhythmias or making them sustained  
2. Slowing of the VT rate below cut-off detection rate for VT  
3. Changing the QRS morphology that causes sensing alteration 
4. Elevation of the DFT.  
5. Elevation of the pacing threshold 
6. Heart failure exacerbation 
Drug effects on the pacing threshold vary with the class of drug and there is little or no 
effect on pacing threshold except class IC agents, especially flecainide [38]. The most 
potentially dangerous effect of drugs on ICD function is an increase in DFT that can lead to 
ineffective ICD therapy [3,36]. Generally, the drugs that block fast inward sodium channel 
and shorten the action potential duration can cause an increase in DFT, while potassium 
channel blocking drugs that prolong the action potential duration (e.g., sotalol) tend to 
decrease DFTs and these drugs are favorable choices in patients with high DFTs [3]. Class IA 
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drugs do not seem to have significant effects on the DFT whereas class IB drugs that block 
fast inward sodium channel (lidocaine and mexiletine) have consistently shown elevation in 
DFT [3,36,39]. The effect of class IC agents on the DFT is less clear. As opposed to the class I 
agents, class III agents tend no effect or to lower the DFT except amiodarone. Intravenous 
amiodarone had no effect on DFT, while oral amiodarone was associated with an increase in 
DFT in animal and human studies and hence DFT should be re-evaluated whenever 
antiarrhythmic agents especially amiodarone is administered [3,36].  
5. ICD-pacemaker ınteractions 
ICD-Pacemaker interactions involve only patients with separate PM and ICD systems 
implanted, which is a very rare scenario nowadays. The potential adverse interaction 
between ICD and pacemaker include [3,40]:  
1. ICD effect on pacemaker function, 
2. Pacemaker effect on ICD function.  
Defibrillation shocks can lead to transient failure of pacemaker sensing and pacing because 
of exposure of the myocardium to high current density [40]. After an ICD shock, pacemaker 
function needs to be evaluated as reprogramming or damage to the PM system can ocur. 
Bipolar pacing systems may be less sensitive to this issue. Another potential adverse effect is 
pacemaker reprogramming during ICD interrogation; this can be prevented by keeping 
adequate spatial separation between the pacemaker and ICD generators. In patients with 
ICDs and separate pacemakers, the pacing stimulation can cause ICD oversensing or 
undersensing and hence result in inappropriate therapy or failure to deliver therapy during 
VT/VF [3,40]. In addition, the electrical artifact between the pacemaker and the ICD lead can 
be oversensed by the ICD and cause inappropriate shocks [3]. 
6. Conclusion 
Evolution of ICD technology allows accurate detection and therapy of arrhythmias, while 
also reducing unnecessary shocks and ineffective therapy. However, patients with ICD-
related problems are increasingly encountered worldwide due the growing number of 
implantations. Regular outpatient follow-up is crucial to find out these problems before 
occurence of clinical manifestations.  
Consequently, clinicians, who may not be electrophysiologists, should use stepwise 
approach (Figure 3), gathered from the patient’s history, physical examination, and device 
interrogation as most problems can be solved by simple ICD reprogramming and/or a 
change in medical therapy. 
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